世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

RNA治療薬市場：製品別（ワクチン、医薬品）、タイプ別（mRNA治療薬、RNA干渉、アンチセンスオリゴヌクレオチド）、適応症別（感染症、希少遺伝子疾患）、エンドユーザー別（病院・クリニック）-2028年までの世界予測


RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028

RNA治療薬市場は、CAGR 5.6%で2023年の137億米ドルから2028年には180億米ドルに成長すると予測されている。市場全体の成長を促進する主な要因としては、RNA技術メーカーだけでなく市場関係者間の提携やパートナー... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年9月15日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		166 171 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

RNA治療薬市場は、CAGR 5.6%で2023年の137億米ドルから2028年には180億米ドルに成長すると予測されている。市場全体の成長を促進する主な要因としては、RNA技術メーカーだけでなく市場関係者間の提携やパートナーシップの増加、さまざまなタイプのRNA治療薬（RNAアプタマー、siRNA、低活性化RNAなど）の用途の増加、COVID-19ブースターワクチンの緊急使用認可や承認の急増などが挙げられます。低分子活性化RNA（siRNA）や環状RNA（circRNA）の出現は、RNA治療薬の範囲を拡大した。

"RNA医薬品は予測期間中に最も高い成長を目撃する"
製品に基づき、RNA治療薬市場は医薬品とワクチンに区分される。2022年にはワクチンが市場シェアの大半を占めたが、予測期間中（2023〜2028年）にはRNA医薬品分野が最も高い成長率を記録した。RNA治療薬市場の成長は、RNA合成とドラッグデリバリーにおける技術進歩の急増によって推進されている。RNAベースの医薬品に対するFDA承認の増加やパイプラインの堅調な増加が、このセグメントの有利な成長の要因となっている。Patisiran、Lumasiran、ViltolarsenなどのRNAベースの薬剤の規制上の承認とその成功した商業化は、いくつかの治療薬メーカーがこの分野に投資することを奨励している。
"mRNA治療薬セグメントは、2022年のRNA治療薬市場で最大のシェアを占めた。"
RNA治療薬市場は、タイプに基づき、RNA干渉（RNAi）治療薬、mRNA治療薬、アンチセンスオリゴヌクレオチド（ASO）治療薬、その他の治療薬に区分される。mRNA治療薬セグメントは、2022年にRNA治療薬市場で最大のシェアを占めた。mRNAベースのCOVID-19ワクチンの成功はまた、感染症に対する効果的なワクチン開発におけるmRNA技術の可能性を示し、mRNA治療薬への関心と投資の増加につながった。2023年8月、CARsgen Therapeutics HoldingsはModerna, Inc.と提携し、CARsgenの治験中のClaudin18.2 CAR T細胞製品候補（CT041）とModernaの治験中のClaudin18.2 mRNAがんワクチンとの併用について調査した。

「希少遺伝性疾患はRNA治療薬市場において有利なセグメントとして浮上している。
適応症に基づき、RNA治療薬市場は感染症、希少遺伝病／遺伝性疾患、その他の適応症に区分される。希少遺伝性疾患は、その有病率の低さと治療パラダイムの難しさによって特徴づけられることが多く、RNAベースの介入が革新的な可能性を持つ機会を生み出している。RNA治療薬は、疾患の原因となる根本的な遺伝子変異を正確に標的とすることで、これらの希少遺伝性疾患に対処するユニークな手段を提供する。低分子干渉RNA（siRNA）を用いた遺伝子サイレンシングやCRISPR/Cas9を用いた遺伝子編集などの技術により、RNA治療薬はこれらの疾患の原因となる遺伝子異常を修正または緩和する。
予測期間を通じて世界のRNA治療薬市場を支配しているのは欧州である。
世界のRNA治療薬市場は、北米、欧州、アジア太平洋地域、その他の地域の4つの主要地域に区分される。欧州はRNAワクチン市場をリードしており、2022年のこのセグメントの売上高シェアは最高である。北米は、2023年から2028年にかけて最も急成長する地域として浮上している。RNAワクチンとRNA医薬品の両方を合わせた欧州の収益シェアは2022年に最も高く、これは予測期間中も続くとみられる。
供給側一次面接の企業タイプ別、呼称別、地域別の内訳：

- 回答者別供給側（70％）、需要側（30）
- 役職別Cレベル(55%)、ディレクターレベル(20%)、その他(25%)
- 地域別北米(50%)、欧州(20%)、アジア太平洋地域(20%)、その他地域(10%)

レポート掲載企業一覧
- モデナ社（米国）
- アルナイラム社（米国）
- ファイザー（米国）
- ノバルティスAG（スイス）
- イオニス・ファーマシューティカルズ（米国）
- サレプタ・セラピューティクス社（米国）
- サノフィ（フランス）
- アローヘッド・ファーマシューティカルズ（米）
- バイオエヌテックSE（ドイツ）
- オルナ・セラピューティクス（米）
- CRISPR セラピューティクス（スイス）
- サイレンス・セラピューティクス（英国）
- アステラス製薬（日本）
- キュアバックSE（ドイツ）
- サーナオミクス（米国）
- アークトゥルス・セラピューティクス（米国）
- アルブタス・バイオファーマ（米国）
調査対象

当レポートでは、RNA治療薬市場を製品、タイプ、適応症、エンドユーザー、地域別に調査しています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争状況の詳細を提供しています。また、微小市場の成長動向、展望、RNA治療薬市場全体への貢献についても調査しています。当レポートでは、4つの主要地域に関して市場セグメントの収益を予測しています。

レポートを購入する理由
本レポートは、以下のポイントに関する洞察を提供します：
.
- 市場促進要因：市場全体の成長を促進する主な要因には、RNA技術メーカーだけでなく、市場プレイヤー間の提携やパートナーシップの増加、さまざまなタイプのRNA治療薬の用途の増加、COVID-19ブースターワクチンの急速な緊急使用認可や承認などがあります。
- 市場への浸透：市場上位17〜20社が提供するRNA治療薬に関する包括的情報。製品、タイプ、適応症、エンドユーザー、地域別にRNA治療薬市場を分析しています。
- 市場の発展：有利な新興市場に関する包括的情報。主要地域にわたる様々な製品/タイプのRNA治療薬/エンドユーザー市場を分析しています。
- 市場の多様化：遺伝子編集市場における未開拓の地域、最近の開発、投資に関する網羅的な情報。
- 競合評価：RNA治療薬市場における主要企業の市場シェアと戦略を詳細に評価

ページTOPに戻る


目次

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS AND EXCLUSIONS 24
1.3 MARKET SCOPE 25
1.3.1 YEARS CONSIDERED 25
1.4 CURRENCY CONSIDERED 26
1.5 RESEARCH LIMITATIONS 26
1.6 STAKEHOLDERS 26
1.6.1 RECESSION IMPACT: RNA THERAPEUTICS MARKET 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 1 RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 29
2.1.2 PRIMARY DATA 29
FIGURE 2 BREAKDOWN OF PRIMARIES: RNA THERAPEUTICS MARKET 30
2.2 MARKET ESTIMATION METHODOLOGY 30
FIGURE 3 RNA THERAPEUTICS MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022 30
FIGURE 4 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2022 31
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 32
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 32
2.3 MARKET GROWTH RATE PROJECTION 33
FIGURE 6 RNA THERAPEUTICS MARKET (SUPPLY SIDE): CAGR PROJECTIONS 34
FIGURE 7 GROWTH ANALYSIS OF DEMAND SIDE DRIVERS: RNA THERAPEUTICS MARKET 34
2.4 MARKET ESTIMATION AND DATA TRIANGULATION 35
FIGURE 8 DATA TRIANGULATION METHODOLOGY 35
2.5 STUDY ASSUMPTIONS 35
2.6 RISK ANALYSIS 36
2.7 IMPACT OF ECONOMIC RECESSION ON RNA THERAPEUTICS MARKET 36
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 36
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 36
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 37
3 EXECUTIVE SUMMARY 38
FIGURE 9 RNA THERAPEUTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 38
FIGURE 10 RNA THERAPEUTICS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 39
FIGURE 11 RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 39
FIGURE 12 RNA THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 40
FIGURE 13 REGIONAL SNAPSHOT: RNA THERAPEUTICS MARKET 41
4 PREMIUM INSIGHTS 42
4.1 RNA THERAPEUTICS MARKET OVERVIEW 42
FIGURE 14 GROWING PARTNERSHIPS AND COLLABORATIONS AMONG KEY PLAYERS TO DRIVE MARKET 42
4.2 NORTH AMERICA: RNA THERAPEUTICS MARKET SHARE, BY PRODUCT AND COUNTRY (2022) 43
FIGURE 15 VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA THERAPEUTICS MARKET IN 2022 43
4.3 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 43
FIGURE 16 INFECTIOUS DISEASES TO DOMINATE NORTH AMERICAN RNA THERAPEUTICS MARKET DURING FORECAST PERIOD 43
5 MARKET OVERVIEW 44
5.1 INTRODUCTION 44
5.2 MARKET DYNAMICS 44
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: RNA THERAPEUTICS MARKET 44
TABLE 4 IMPACT ANALYSIS: RNA THERAPEUTICS MARKET 45
5.2.1 DRIVERS 45
5.2.1.1 Increasing partnerships and collaborations between market players and RNA technology manufacturers 45
5.2.1.2 Increasing number of novel modalities for RNA therapeutics 46
5.2.1.3 Growing number of emergency use authorizations and approvals for COVID-19 booster vaccines 47
5.2.2 RESTRAINTS 48
5.2.2.1 Discontinuation or recalls of RNA therapeutic products 48
TABLE 5 LIST OF RNA THERAPEUTICS FOR WHICH CLINICAL DEVELOPMENT WAS HALTED 48
5.2.3 OPPORTUNITIES 49
5.2.3.1 Higher progress in development of RNA aptamer-based therapeutics 49
TABLE 6 RNA APTAMERS UNDER CLINICAL DEVELOPMENT 49
5.2.4 CHALLENGES 50
5.2.4.1 Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA 50
5.3 TECHNOLOGY ANALYSIS (RNA VACCINE AND THERAPY MANUFACTURING) 51
5.3.1 PARAMETERS OF MANUFACTURING 51
5.3.2 CIRCULAR RNA ENGINEERING 51
5.4 PIPELINE ANALYSIS 52
FIGURE 18 PIPELINE THERAPIES, BY CATEGORY, 2022 52
5.4.1 PIPELINE ANALYSIS FOR KEY MARKET PLAYERS (TOP 5) 52
5.4.1.1 Moderna, Inc. 52
TABLE 7 PIPELINE CANDIDATES OF MODERNA, INC. 52
5.4.1.2 Pfizer, Inc. 54
TABLE 8 PIPELINE CANDIDATES OF PFIZER INC. 54
5.4.1.3 Alnylam Pharmaceuticals, Inc. 54
TABLE 9 PIPELINE CANDIDATES OF ALNYLAM PHARMACEUTICALS, INC. 54
5.4.1.4 Novartis AG 55
TABLE 10 PIPELINE CANDIDATES OF NOVARTIS AG 55
5.4.1.5 Ionis Pharmaceuticals, Inc. 55
TABLE 11 PIPELINE CANDIDATES OF IONIS PHARMACEUTICALS, INC. 55
5.5 PORTER’S FIVE FORCES ANALYSIS 56
TABLE 12 PORTER’S FIVE FORCES ANALYSIS: RNA THERAPEUTICS MARKET 56
5.5.1 THREAT OF NEW ENTRANTS 56
5.5.2 THREAT OF SUBSTITUTES 57
5.5.3 BARGAINING POWER OF BUYERS 57
5.5.4 BARGAINING POWER OF SUPPLIERS 57
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 57
5.6 REGULATORY ANALYSIS 58
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
5.7 VALUE CHAIN ANALYSIS 60
FIGURE 19 VALUE CHAIN ANALYSIS OF RNA THERAPEUTICS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE 60
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 61
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 61
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA-BASED THERAPEUTICS 61
5.9.2 BUYING CRITERIA FOR RNA THERAPEUTIC PRODUCTS/MEDICINES 62
FIGURE 22 KEY BUYING CRITERIA FOR END USERS 62
5.10 PRICING ANALYSIS 62
5.10.1 PRICING ANALYSIS FOR FDA-APPROVED RNA THERAPEUTICS, BY PRODUCT 62
TABLE 17 AVERAGE SELLING PRICE FOR RNA VACCINES AND DRUGS, BY REGION 62
5.10.2 PRICING TREND ANALYSIS: RNA VACCINES AND DRUGS 63
5.11 KEY CONFERENCES AND EVENTS (2023–2024) 63
TABLE 18 KEY CONFERENCES AND EVENTS IN RNA THERAPEUTICS MARKET (2023–2024) 63
5.12 ECOSYSTEM MARKET MAP 64
6 RNA THERAPEUTICS MARKET, BY PRODUCT 65
6.1 INTRODUCTION 66
TABLE 19 RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 66
6.2 VACCINES 66
6.2.1 INCREASED NUMBER OF APPROVALS AND HIGHER INVESTMENTS FOR COVID-19 BOOSTER VACCINES TO DRIVE MARKET 66
TABLE 20 RNA THERAPEUTICS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 67
TABLE 21 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 67
TABLE 22 EUROPE: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 67
TABLE 23 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 68
6.3 DRUGS 68
6.3.1 GROWING FUNDING AND INVESTMENTS IN RNA THERAPEUTICS RESEARCH TO DRIVE MARKET 68
TABLE 24 RNA THERAPEUTICS MARKET FOR DRUGS, BY REGION, 2021–2028 (USD MILLION) 68
TABLE 25 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 69
TABLE 26 EUROPE: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 69
TABLE 27 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 69
7 RNA THERAPEUTICS MARKET, BY TYPE 70
7.1 INTRODUCTION 71
TABLE 28 RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 71
7.2 MRNA THERAPEUTICS 71
7.2.1 INCREASING INVESTMENTS FOR COVID-19 MRNA VACCINES TO DRIVE MARKET 71
TABLE 29 RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 72
TABLE 30 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 31 EUROPE: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 32 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 73
7.3 RNA INTERFERENCE (RNAI) THERAPEUTICS 74
7.3.1 INCREASING NUMBER OF APPROVALS FOR SIRNA THERAPEUTICS BY US FDA TO DRIVE MARKET 74
TABLE 33 RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 34 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 35 EUROPE: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 36 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 75
7.4 ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS 76
7.4.1 INCREASED NUMBER OF CHEMICAL MODIFICATIONS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 76
TABLE 37 RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 76
TABLE 38 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 39 EUROPE: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 40 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 77
7.5 OTHER THERAPEUTICS 78
8 RNA THERAPEUTICS MARKET, BY INDICATION 79
8.1 INTRODUCTION 80
TABLE 41 RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 80
8.2 INFECTIOUS DISEASES 80
8.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND GROWING INVESTMENTS IN R&D TO DRIVE MARKET 80
TABLE 42 RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 43 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 44 EUROPE: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 45 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 82
8.3 RARE GENETIC/HEREDITARY DISEASES 82
8.3.1 TECHNOLOGICAL INNOVATION AND INCREASED DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET 82
TABLE 46 RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 47 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 48 EUROPE: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 49 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 84
8.4 OTHER INDICATIONS 84
TABLE 50 RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 51 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 52 EUROPE: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 53 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 86
9 RNA THERAPEUTICS MARKET, BY END USER 87
9.1 INTRODUCTION 88
TABLE 54 RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 88
9.2 HOSPITALS AND CLINICS 88
9.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND HIGHER EFFICACY OF RNA-BASED THERAPIES TO DRIVE MARKET 88
TABLE 55 RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 56 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 57 EUROPE: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 58 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 90
9.3 RESEARCH SETTINGS 90
9.3.1 HIGHER THERAPEUTIC POTENTIAL OF RNA TECHNOLOGY TO CREATE NEW OPPORTUNITIES IN MEDICAL RESEARCH 90
TABLE 59 RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 60 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 61 EUROPE: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 62 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 92
10 RNA THERAPEUTICS MARKET, BY REGION 93
10.1 INTRODUCTION 94
TABLE 63 RNA THERAPEUTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
10.2 NORTH AMERICA 94
FIGURE 23 NORTH AMERICA: RNA THERAPEUTICS MARKET SNAPSHOT 95
TABLE 64 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 65 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 96
TABLE 66 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 96
TABLE 67 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 96
TABLE 68 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 97
10.2.1 NORTH AMERICA: RECESSION IMPACT 97
10.2.2 US 98
10.2.2.1 Growing technological innovation in RNA delivery systems and rising investments in biopharmaceutical research to drive market 98
TABLE 69 LIST OF RECENT RNA THERAPEUTICS APPROVED BY FDA 98
TABLE 70 US: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99
TABLE 71 US: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 99
TABLE 72 US: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 99
TABLE 73 US: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 100
10.2.3 CANADA 100
10.2.3.1 Increasing government initiatives and investments for life science research to drive market 100
TABLE 74 CANADA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 101
TABLE 75 CANADA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 101
TABLE 76 CANADA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 101
TABLE 77 CANADA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 102
10.3 EUROPE 102
TABLE 78 EUROPE: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 79 EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103
TABLE 80 EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 103
TABLE 81 EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 103
TABLE 82 EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 104
10.3.1 EUROPE: RECESSION IMPACT 104
10.3.2 GERMANY 104
10.3.2.1 Rising number of market players and growing public and private funding for research activities to drive market 104
TABLE 83 GERMANY: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 105
TABLE 84 GERMANY: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 105
TABLE 85 GERMANY: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 106
TABLE 86 GERMANY: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
10.3.3 FRANCE 106
10.3.3.1 Growing pharmaceutical manufacturing industry and increasing number of clinical trials for oncology to drive market 106
TABLE 87 FRANCE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 107
TABLE 88 FRANCE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
TABLE 89 FRANCE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 107
TABLE 90 FRANCE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 108
10.3.4 UK 108
10.3.4.1 Higher R&D investment by pharmaceutical companies for RNA-based drug discovery to drive market 108
TABLE 91 UK: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 109
TABLE 92 UK: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 93 UK: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 109
TABLE 94 UK: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 110
10.3.5 REST OF EUROPE 110
TABLE 95 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 110
TABLE 96 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 97 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 111
TABLE 98 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
10.4 ASIA PACIFIC 112
FIGURE 24 ASIA PACIFIC: RNA THERAPEUTICS MARKET SNAPSHOT 113
TABLE 99 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 100 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 114
TABLE 101 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 102 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 115
TABLE 103 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 115
10.4.1 ASIA PACIFIC: RECESSION IMPACT 115
10.4.2 JAPAN 116
10.4.2.1 Increasing geriatric population and rising government initiatives for drug innovation to drive market 116
TABLE 104 JAPAN: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 116
TABLE 105 JAPAN: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 106 JAPAN: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 117
TABLE 107 JAPAN: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 117
10.4.3 CHINA 118
10.4.3.1 Low manufacturing costs and increased number of R&D activities to drive market 118
TABLE 108 CHINA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 118
TABLE 109 CHINA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 110 CHINA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 119
TABLE 111 CHINA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.4.4 SOUTH KOREA 120
10.4.4.1 Increasing number of government initiatives and growing R&D activities for RNA therapeutics to drive market 120
TABLE 112 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 120
TABLE 113 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 114 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 121
TABLE 115 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.4.5 REST OF ASIA PACIFIC 121
TABLE 116 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 122
TABLE 117 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 118 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 122
TABLE 119 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 123
10.5 REST OF THE WORLD 123
TABLE 120 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 121 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 122 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 124
TABLE 123 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 124
11 COMPETITIVE LANDSCAPE 125
11.1 OVERVIEW 125
11.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RNA THERAPEUTICS MARKET 126
FIGURE 25 KEY PLAYER STRATEGIES IN RNA THERAPEUTICS MARKET, 2021–2023 126
11.3 MARKET SHARE ANALYSIS 127
FIGURE 26 MARKET SHARE ANALYSIS OF TOP 3 PLAYERS IN RNA THERAPEUTICS MARKET, 2022 127
TABLE 124 DEGREE OF COMPETITION: RNA THERAPEUTICS MARKET 127
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 129
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP 4 PLAYERS IN RNA THERAPEUTICS MARKET, 2020–2022 129
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 129
11.5.1 STARS 129
11.5.2 EMERGING LEADERS 130
11.5.3 PERVASIVE PLAYERS 130
11.5.4 PARTICIPANTS 130
FIGURE 28 COMPANY EVALUATION MATRIX FOR KEY PLAYERS: RNA THERAPEUTICS MARKET, 2022 131
11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES 132
11.6.1 PROGRESSIVE COMPANIES 132
11.6.2 STARTING BLOCKS 132
11.6.3 DYNAMIC COMPANIES 132
11.6.4 RESPONSIVE COMPANIES 132
FIGURE 29 COMPANY EVALUATION MATRIX FOR START-UPS/SMES: RNA THERAPEUTICS MARKET, 2022 133
11.7 COMPETITIVE BENCHMARKING 134
TABLE 125 DETAILED LIST OF KEY START-UPS/SMES: RNA THERAPEUTICS MARKET 134
11.8 COMPETITIVE SCENARIOS AND TRENDS 135
11.8.1 KEY PRODUCT APPROVALS 135
TABLE 126 KEY PRODUCT APPROVALS, JANUARY 2021–AUGUST 2023 135
11.8.2 KEY DEALS 135
TABLE 127 KEY DEALS, JANUARY 2021–AUGUST 2023 135
11.8.3 OTHER KEY DEVELOPMENTS 136
TABLE 128 OTHER KEY DEVELOPMENTS, JANUARY 2021–AUGUST 2023 136
12 COMPANY PROFILES 137
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS 137
12.1.1 MODERNA, INC. 137
TABLE 129 MODERNA, INC.: COMPANY OVERVIEW 137
FIGURE 30 MODERNA, INC.: COMPANY SNAPSHOT (2022) 138
12.1.2 ALNYLAM PHARMACEUTICALS, INC. 142
TABLE 130 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 142
FIGURE 31 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022) 142
12.1.3 NOVARTIS AG 145
TABLE 131 NOVARTIS AG: COMPANY OVERVIEW 145
FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2022) 146
12.1.4 IONIS PHARMACEUTICALS, INC. 149
TABLE 132 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 149
FIGURE 33 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022) 149
12.1.5 SAREPTA THERAPEUTICS, INC. 153
TABLE 133 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 153
FIGURE 34 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2022) 153
12.1.6 SANOFI 155
TABLE 134 SANOFI: COMPANY OVERVIEW 155
FIGURE 35 SANOFI: COMPANY SNAPSHOT (2022) 156
12.1.7 PFIZER INC. 158
TABLE 135 PFIZER INC.: COMPANY OVERVIEW 158
FIGURE 36 PFIZER INC.: COMPANY SNAPSHOT (2022) 159
12.2 OTHER PLAYERS 161
12.2.1 ARROWHEAD PHARMACEUTICALS, INC. 161
12.2.2 BIONTECH SE 161
12.2.3 ORNA THERAPEUTICS 162
12.2.4 CRISPR THERAPEUTICS 162
12.2.5 SILENCE THERAPEUTICS 163
12.2.6 ASTELLAS PHARMA INC. 163
12.2.7 CUREVAC SE 164
12.2.8 SIRNAOMICS 164
12.2.9 ARCTURUS THERAPEUTICS, INC. 165
12.2.10 ARBUTUS BIOPHARMA 165
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX 166
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 168
13.2 CUSTOMIZATION OPTIONS 170
13.3 RELATED REPORTS 170
13.4 AUTHOR DETAILS 171

　

ページTOPに戻る


　

Summary

The RNA therapeutics market is projected to grow from USD 13.7 billion in 2023 to USD 18.0 billion by 2028 at a CAGR of 5.6%. The key factors driving the overall market growth include an increase in the number of collaborations and partnerships among market players as well as RNA technology manufacturers, an increase in applications of different types of RNA therapeutics (such as RNA aptamers, siRNA, small-activating RNA), and the rapid emergency use authorizations and approvals for COVID-19 booster vaccines. The emergence of small activating RNAs (siRNAs) and circular RNAs (circRNAs) has expanded the scope of RNA therapeutics.

“RNA drugs to witness the highest growth during the forecast period.”
Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented the majority of the market share, whereas the RNA drugs segment registered the highest growth rate during the forecast period (2023-2028). The growth of the RNA therapeutics drugs market is propelled by a surge in technological advancements in RNA synthesis and drug delivery. The increasing number of FDA approvals for RNA-based drugs and robust increase in the pipeline are attributive to the segment’s lucrative growth. Regulatory approvals of RNA-based drugs, such as Patisiran, Lumasiran, and Viltolarsen, and their successful commercialization have encouraged several therapeutics manufacturers to invest in this space.
“The mRNA therapeutics segment accounted for the largest share in the RNA therapeutics market in 2022.”
Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. The mRNA therapeutics segment accounted for the largest share of the RNA therapeutics market in 2022. The success of mRNA-based COVID-19 vaccines has also demonstrated the potential of mRNA technology in developing effective vaccines against infectious diseases, leading to increased interest and investment in mRNA therapeutics. In August 2023, CARsgen Therapeutics Holdings collaborated with Moderna, Inc. to investigate CARsgen's investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine.

“Rare genetic/hereditary diseases have emerged as a lucrative segment in the RNA therapeutics market.”
Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. Rare genetic diseases, often characterized by their limited prevalence and challenging treatment paradigms, create opportunities for the innovative potential of RNA-based interventions. RNA therapeutics offer a unique avenue to address these rare genetic disorders by precisely targeting the underlying genetic mutations that are responsible for the diseases. Through techniques such as gene silencing using small interfering RNAs (siRNAs) or gene editing using CRISPR/Cas9, RNA therapeutics correct or mitigate the genetic abnormalities causing these conditions.
Europe dominates the global RNA therapeutics market throughout the forecast period.
The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with the highest share of revenue in this segment in 2022. North America has emerged as the fastest-growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs, is highest in 2022, and this is set to continue through the forecast period.
Breakdown of supply-side primary interviews by company type, designation, and region:

• By Respondent: Supply Side (70%), Demand side (30%)
• By Designation: C-level (55%), Director-level (20%), and Others (25%)
• By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

List of Companies Profiled in the Report
• Moderna, Inc. (US)
• Alnylam Pharmaceuticals, Inc. (US)
• Pfizer Inc. (US)
• Novartis AG (Switzerland)
• Ionis Pharmaceuticals, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Sanofi (France)
• Arrowhead Pharmaceuticals, Inc. (US)
• BioNtech SE (Germany)
• Orna Therapeutics (US)
• CRISPR Therapeutics (Switzerland)
• Silence Therapeutics (UK)
• Astellas Pharma Inc. (Japan)
• CureVac SE (Germany)
• Sirnaomics (US)
• Arcturus Therapeutics Inc. (US)
• Arbutus Biopharma (US)
Research Coverage

This report studies the RNA therapeutics market based on product, type, indication, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total RNA therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
.
• Market Drivers: The key factors driving the overall market growth include an increase in the number of collaborations and partnerships among market players as well as RNA technology manufacturers, an increase in applications of different types of RNA therapeutics and the rapid emergency use authorizations and approvals for COVID-19 booster vaccines.
• Market Penetration: Comprehensive information on RNA therapeutics offered by the top 17-20 players in the market. The report analyzes the RNA therapeutics market by product, type, indication, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of RNA therapeutics/end users across key geographic regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the gene editing market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the RNA therapeutics market



ページTOPに戻る


Table of Contents

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS AND EXCLUSIONS 24
1.3 MARKET SCOPE 25
1.3.1 YEARS CONSIDERED 25
1.4 CURRENCY CONSIDERED 26
1.5 RESEARCH LIMITATIONS 26
1.6 STAKEHOLDERS 26
1.6.1 RECESSION IMPACT: RNA THERAPEUTICS MARKET 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 1 RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 29
2.1.2 PRIMARY DATA 29
FIGURE 2 BREAKDOWN OF PRIMARIES: RNA THERAPEUTICS MARKET 30
2.2 MARKET ESTIMATION METHODOLOGY 30
FIGURE 3 RNA THERAPEUTICS MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022 30
FIGURE 4 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2022 31
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 32
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 32
2.3 MARKET GROWTH RATE PROJECTION 33
FIGURE 6 RNA THERAPEUTICS MARKET (SUPPLY SIDE): CAGR PROJECTIONS 34
FIGURE 7 GROWTH ANALYSIS OF DEMAND SIDE DRIVERS: RNA THERAPEUTICS MARKET 34
2.4 MARKET ESTIMATION AND DATA TRIANGULATION 35
FIGURE 8 DATA TRIANGULATION METHODOLOGY 35
2.5 STUDY ASSUMPTIONS 35
2.6 RISK ANALYSIS 36
2.7 IMPACT OF ECONOMIC RECESSION ON RNA THERAPEUTICS MARKET 36
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 36
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 36
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 37
3 EXECUTIVE SUMMARY 38
FIGURE 9 RNA THERAPEUTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 38
FIGURE 10 RNA THERAPEUTICS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 39
FIGURE 11 RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 39
FIGURE 12 RNA THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 40
FIGURE 13 REGIONAL SNAPSHOT: RNA THERAPEUTICS MARKET 41
4 PREMIUM INSIGHTS 42
4.1 RNA THERAPEUTICS MARKET OVERVIEW 42
FIGURE 14 GROWING PARTNERSHIPS AND COLLABORATIONS AMONG KEY PLAYERS TO DRIVE MARKET 42
4.2 NORTH AMERICA: RNA THERAPEUTICS MARKET SHARE, BY PRODUCT AND COUNTRY (2022) 43
FIGURE 15 VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA THERAPEUTICS MARKET IN 2022 43
4.3 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 43
FIGURE 16 INFECTIOUS DISEASES TO DOMINATE NORTH AMERICAN RNA THERAPEUTICS MARKET DURING FORECAST PERIOD 43
5 MARKET OVERVIEW 44
5.1 INTRODUCTION 44
5.2 MARKET DYNAMICS 44
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: RNA THERAPEUTICS MARKET 44
TABLE 4 IMPACT ANALYSIS: RNA THERAPEUTICS MARKET 45
5.2.1 DRIVERS 45
5.2.1.1 Increasing partnerships and collaborations between market players and RNA technology manufacturers 45
5.2.1.2 Increasing number of novel modalities for RNA therapeutics 46
5.2.1.3 Growing number of emergency use authorizations and approvals for COVID-19 booster vaccines 47
5.2.2 RESTRAINTS 48
5.2.2.1 Discontinuation or recalls of RNA therapeutic products 48
TABLE 5 LIST OF RNA THERAPEUTICS FOR WHICH CLINICAL DEVELOPMENT WAS HALTED 48
5.2.3 OPPORTUNITIES 49
5.2.3.1 Higher progress in development of RNA aptamer-based therapeutics 49
TABLE 6 RNA APTAMERS UNDER CLINICAL DEVELOPMENT 49
5.2.4 CHALLENGES 50
5.2.4.1 Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA 50
5.3 TECHNOLOGY ANALYSIS (RNA VACCINE AND THERAPY MANUFACTURING) 51
5.3.1 PARAMETERS OF MANUFACTURING 51
5.3.2 CIRCULAR RNA ENGINEERING 51
5.4 PIPELINE ANALYSIS 52
FIGURE 18 PIPELINE THERAPIES, BY CATEGORY, 2022 52
5.4.1 PIPELINE ANALYSIS FOR KEY MARKET PLAYERS (TOP 5) 52
5.4.1.1 Moderna, Inc. 52
TABLE 7 PIPELINE CANDIDATES OF MODERNA, INC. 52
5.4.1.2 Pfizer, Inc. 54
TABLE 8 PIPELINE CANDIDATES OF PFIZER INC. 54
5.4.1.3 Alnylam Pharmaceuticals, Inc. 54
TABLE 9 PIPELINE CANDIDATES OF ALNYLAM PHARMACEUTICALS, INC. 54
5.4.1.4 Novartis AG 55
TABLE 10 PIPELINE CANDIDATES OF NOVARTIS AG 55
5.4.1.5 Ionis Pharmaceuticals, Inc. 55
TABLE 11 PIPELINE CANDIDATES OF IONIS PHARMACEUTICALS, INC. 55
5.5 PORTER’S FIVE FORCES ANALYSIS 56
TABLE 12 PORTER’S FIVE FORCES ANALYSIS: RNA THERAPEUTICS MARKET 56
5.5.1 THREAT OF NEW ENTRANTS 56
5.5.2 THREAT OF SUBSTITUTES 57
5.5.3 BARGAINING POWER OF BUYERS 57
5.5.4 BARGAINING POWER OF SUPPLIERS 57
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 57
5.6 REGULATORY ANALYSIS 58
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 59
5.7 VALUE CHAIN ANALYSIS 60
FIGURE 19 VALUE CHAIN ANALYSIS OF RNA THERAPEUTICS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE 60
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 61
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 61
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA-BASED THERAPEUTICS 61
5.9.2 BUYING CRITERIA FOR RNA THERAPEUTIC PRODUCTS/MEDICINES 62
FIGURE 22 KEY BUYING CRITERIA FOR END USERS 62
5.10 PRICING ANALYSIS 62
5.10.1 PRICING ANALYSIS FOR FDA-APPROVED RNA THERAPEUTICS, BY PRODUCT 62
TABLE 17 AVERAGE SELLING PRICE FOR RNA VACCINES AND DRUGS, BY REGION 62
5.10.2 PRICING TREND ANALYSIS: RNA VACCINES AND DRUGS 63
5.11 KEY CONFERENCES AND EVENTS (2023–2024) 63
TABLE 18 KEY CONFERENCES AND EVENTS IN RNA THERAPEUTICS MARKET (2023–2024) 63
5.12 ECOSYSTEM MARKET MAP 64
6 RNA THERAPEUTICS MARKET, BY PRODUCT 65
6.1 INTRODUCTION 66
TABLE 19 RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 66
6.2 VACCINES 66
6.2.1 INCREASED NUMBER OF APPROVALS AND HIGHER INVESTMENTS FOR COVID-19 BOOSTER VACCINES TO DRIVE MARKET 66
TABLE 20 RNA THERAPEUTICS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 67
TABLE 21 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 67
TABLE 22 EUROPE: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 67
TABLE 23 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 68
6.3 DRUGS 68
6.3.1 GROWING FUNDING AND INVESTMENTS IN RNA THERAPEUTICS RESEARCH TO DRIVE MARKET 68
TABLE 24 RNA THERAPEUTICS MARKET FOR DRUGS, BY REGION, 2021–2028 (USD MILLION) 68
TABLE 25 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 69
TABLE 26 EUROPE: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 69
TABLE 27 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 69
7 RNA THERAPEUTICS MARKET, BY TYPE 70
7.1 INTRODUCTION 71
TABLE 28 RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 71
7.2 MRNA THERAPEUTICS 71
7.2.1 INCREASING INVESTMENTS FOR COVID-19 MRNA VACCINES TO DRIVE MARKET 71
TABLE 29 RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 72
TABLE 30 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 31 EUROPE: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 32 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 73
7.3 RNA INTERFERENCE (RNAI) THERAPEUTICS 74
7.3.1 INCREASING NUMBER OF APPROVALS FOR SIRNA THERAPEUTICS BY US FDA TO DRIVE MARKET 74
TABLE 33 RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 34 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 35 EUROPE: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 36 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 75
7.4 ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS 76
7.4.1 INCREASED NUMBER OF CHEMICAL MODIFICATIONS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 76
TABLE 37 RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION) 76
TABLE 38 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 39 EUROPE: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 40 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION) 77
7.5 OTHER THERAPEUTICS 78
8 RNA THERAPEUTICS MARKET, BY INDICATION 79
8.1 INTRODUCTION 80
TABLE 41 RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 80
8.2 INFECTIOUS DISEASES 80
8.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND GROWING INVESTMENTS IN R&D TO DRIVE MARKET 80
TABLE 42 RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 43 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 44 EUROPE: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 45 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 82
8.3 RARE GENETIC/HEREDITARY DISEASES 82
8.3.1 TECHNOLOGICAL INNOVATION AND INCREASED DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET 82
TABLE 46 RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 47 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 48 EUROPE: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 49 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 84
8.4 OTHER INDICATIONS 84
TABLE 50 RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 51 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 52 EUROPE: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 53 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 86
9 RNA THERAPEUTICS MARKET, BY END USER 87
9.1 INTRODUCTION 88
TABLE 54 RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 88
9.2 HOSPITALS AND CLINICS 88
9.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND HIGHER EFFICACY OF RNA-BASED THERAPIES TO DRIVE MARKET 88
TABLE 55 RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 56 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 57 EUROPE: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 58 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 90
9.3 RESEARCH SETTINGS 90
9.3.1 HIGHER THERAPEUTIC POTENTIAL OF RNA TECHNOLOGY TO CREATE NEW OPPORTUNITIES IN MEDICAL RESEARCH 90
TABLE 59 RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 60 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 61 EUROPE: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 62 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION) 92
10 RNA THERAPEUTICS MARKET, BY REGION 93
10.1 INTRODUCTION 94
TABLE 63 RNA THERAPEUTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
10.2 NORTH AMERICA 94
FIGURE 23 NORTH AMERICA: RNA THERAPEUTICS MARKET SNAPSHOT 95
TABLE 64 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 65 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 96
TABLE 66 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 96
TABLE 67 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 96
TABLE 68 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 97
10.2.1 NORTH AMERICA: RECESSION IMPACT 97
10.2.2 US 98
10.2.2.1 Growing technological innovation in RNA delivery systems and rising investments in biopharmaceutical research to drive market 98
TABLE 69 LIST OF RECENT RNA THERAPEUTICS APPROVED BY FDA 98
TABLE 70 US: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99
TABLE 71 US: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 99
TABLE 72 US: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 99
TABLE 73 US: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 100
10.2.3 CANADA 100
10.2.3.1 Increasing government initiatives and investments for life science research to drive market 100
TABLE 74 CANADA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 101
TABLE 75 CANADA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 101
TABLE 76 CANADA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 101
TABLE 77 CANADA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 102
10.3 EUROPE 102
TABLE 78 EUROPE: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 79 EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103
TABLE 80 EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 103
TABLE 81 EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 103
TABLE 82 EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 104
10.3.1 EUROPE: RECESSION IMPACT 104
10.3.2 GERMANY 104
10.3.2.1 Rising number of market players and growing public and private funding for research activities to drive market 104
TABLE 83 GERMANY: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 105
TABLE 84 GERMANY: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 105
TABLE 85 GERMANY: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 106
TABLE 86 GERMANY: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
10.3.3 FRANCE 106
10.3.3.1 Growing pharmaceutical manufacturing industry and increasing number of clinical trials for oncology to drive market 106
TABLE 87 FRANCE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 107
TABLE 88 FRANCE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
TABLE 89 FRANCE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 107
TABLE 90 FRANCE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 108
10.3.4 UK 108
10.3.4.1 Higher R&D investment by pharmaceutical companies for RNA-based drug discovery to drive market 108
TABLE 91 UK: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 109
TABLE 92 UK: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 93 UK: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 109
TABLE 94 UK: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 110
10.3.5 REST OF EUROPE 110
TABLE 95 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 110
TABLE 96 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 97 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 111
TABLE 98 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
10.4 ASIA PACIFIC 112
FIGURE 24 ASIA PACIFIC: RNA THERAPEUTICS MARKET SNAPSHOT 113
TABLE 99 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 100 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 114
TABLE 101 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 102 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 115
TABLE 103 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 115
10.4.1 ASIA PACIFIC: RECESSION IMPACT 115
10.4.2 JAPAN 116
10.4.2.1 Increasing geriatric population and rising government initiatives for drug innovation to drive market 116
TABLE 104 JAPAN: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 116
TABLE 105 JAPAN: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 106 JAPAN: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 117
TABLE 107 JAPAN: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 117
10.4.3 CHINA 118
10.4.3.1 Low manufacturing costs and increased number of R&D activities to drive market 118
TABLE 108 CHINA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 118
TABLE 109 CHINA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 110 CHINA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 119
TABLE 111 CHINA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.4.4 SOUTH KOREA 120
10.4.4.1 Increasing number of government initiatives and growing R&D activities for RNA therapeutics to drive market 120
TABLE 112 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 120
TABLE 113 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 114 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 121
TABLE 115 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.4.5 REST OF ASIA PACIFIC 121
TABLE 116 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 122
TABLE 117 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 118 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 122
TABLE 119 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 123
10.5 REST OF THE WORLD 123
TABLE 120 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 121 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 122 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 124
TABLE 123 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 124
11 COMPETITIVE LANDSCAPE 125
11.1 OVERVIEW 125
11.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RNA THERAPEUTICS MARKET 126
FIGURE 25 KEY PLAYER STRATEGIES IN RNA THERAPEUTICS MARKET, 2021–2023 126
11.3 MARKET SHARE ANALYSIS 127
FIGURE 26 MARKET SHARE ANALYSIS OF TOP 3 PLAYERS IN RNA THERAPEUTICS MARKET, 2022 127
TABLE 124 DEGREE OF COMPETITION: RNA THERAPEUTICS MARKET 127
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 129
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP 4 PLAYERS IN RNA THERAPEUTICS MARKET, 2020–2022 129
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 129
11.5.1 STARS 129
11.5.2 EMERGING LEADERS 130
11.5.3 PERVASIVE PLAYERS 130
11.5.4 PARTICIPANTS 130
FIGURE 28 COMPANY EVALUATION MATRIX FOR KEY PLAYERS: RNA THERAPEUTICS MARKET, 2022 131
11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES 132
11.6.1 PROGRESSIVE COMPANIES 132
11.6.2 STARTING BLOCKS 132
11.6.3 DYNAMIC COMPANIES 132
11.6.4 RESPONSIVE COMPANIES 132
FIGURE 29 COMPANY EVALUATION MATRIX FOR START-UPS/SMES: RNA THERAPEUTICS MARKET, 2022 133
11.7 COMPETITIVE BENCHMARKING 134
TABLE 125 DETAILED LIST OF KEY START-UPS/SMES: RNA THERAPEUTICS MARKET 134
11.8 COMPETITIVE SCENARIOS AND TRENDS 135
11.8.1 KEY PRODUCT APPROVALS 135
TABLE 126 KEY PRODUCT APPROVALS, JANUARY 2021–AUGUST 2023 135
11.8.2 KEY DEALS 135
TABLE 127 KEY DEALS, JANUARY 2021–AUGUST 2023 135
11.8.3 OTHER KEY DEVELOPMENTS 136
TABLE 128 OTHER KEY DEVELOPMENTS, JANUARY 2021–AUGUST 2023 136
12 COMPANY PROFILES 137
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS 137
12.1.1 MODERNA, INC. 137
TABLE 129 MODERNA, INC.: COMPANY OVERVIEW 137
FIGURE 30 MODERNA, INC.: COMPANY SNAPSHOT (2022) 138
12.1.2 ALNYLAM PHARMACEUTICALS, INC. 142
TABLE 130 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 142
FIGURE 31 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022) 142
12.1.3 NOVARTIS AG 145
TABLE 131 NOVARTIS AG: COMPANY OVERVIEW 145
FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2022) 146
12.1.4 IONIS PHARMACEUTICALS, INC. 149
TABLE 132 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 149
FIGURE 33 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022) 149
12.1.5 SAREPTA THERAPEUTICS, INC. 153
TABLE 133 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 153
FIGURE 34 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2022) 153
12.1.6 SANOFI 155
TABLE 134 SANOFI: COMPANY OVERVIEW 155
FIGURE 35 SANOFI: COMPANY SNAPSHOT (2022) 156
12.1.7 PFIZER INC. 158
TABLE 135 PFIZER INC.: COMPANY OVERVIEW 158
FIGURE 36 PFIZER INC.: COMPANY SNAPSHOT (2022) 159
12.2 OTHER PLAYERS 161
12.2.1 ARROWHEAD PHARMACEUTICALS, INC. 161
12.2.2 BIONTECH SE 161
12.2.3 ORNA THERAPEUTICS 162
12.2.4 CRISPR THERAPEUTICS 162
12.2.5 SILENCE THERAPEUTICS 163
12.2.6 ASTELLAS PHARMA INC. 163
12.2.7 CUREVAC SE 164
12.2.8 SIRNAOMICS 164
12.2.9 ARCTURUS THERAPEUTICS, INC. 165
12.2.10 ARBUTUS BIOPHARMA 165
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX 166
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 168
13.2 CUSTOMIZATION OPTIONS 170
13.3 RELATED REPORTS 170
13.4 AUTHOR DETAILS 171

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（therapeutics）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22　10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.